Statins but Not Aspirin Reduce Thrombotic Risk Assessed by Thrombin Generation in Diabetic Patients without Cardiovascular Events: The RATIONAL Trial

Abstract

BackgroundThe systematic use of aspirin and statins in patients with diabetes and no previous cardiovascular events is controversial. We sought to assess the effects of aspirin and statins on the thrombotic risk assessed by thrombin generation (TG) among patients with type II diabetes mellitus and no previous cardiovascular events.Methodology/Principal FindingsProspective, randomized, open, blinded to events evaluation, controlled, 2×2 factorial clinical trial including 30 patients randomly allocated to aspirin 100 mg/d, atorvastatin 40 mg/d, both or none. Outcome measurements included changes in TG levels after treatment (8 to 10 weeks), assessed by a calibrated automated thrombogram. At baseline all groups had similar clinical and biochemical profiles, including TG levels. There was no interaction between aspirin and atorvastatin. Atorvastatin significantly reduced TG measured as peak TG with saline (85.09±55.34 nmol vs 153.26±75.55 nmol for atorvastatin and control groups, respectively; p = 0.018). On the other hand, aspirin had no effect on TG (121.51±81.83 nmol vs 116.85±67.66 nmol, for aspirin and control groups, respectively; p = 0.716). The effects of treatments on measurements of TG using other agonists were consistent.Conclusions/SignificanceWhile waiting for data from ongoing large clinical randomized trials to definitively outline the role of aspirin in primary prevention, our study shows that among diabetic patients without previous vascular events, statins but not aspirin reduce thrombotic risk assessed by TG.Trial RegistrationClinicalTrials.gov NCT00793754

Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial

“…In this randomized clinical trial (START), we have shown that treatment with rosuvastatin leads to a relative reduction in thrombin generation potential, decreasing the ETP by 10.4% (adjusted mean difference between treatments, −129.39 n m *min) and decreasing the thrombin peak by 5% (adjusted mean difference between treatments, −13.69 n m ), in comparison with non‐statin treatment. Our results confirm previous clinical studies that also demonstrated that statin therapy, either with rosuvastatin , simvastatin , atorvastatin or cerivastatin , affects coagulation factors and thrombin generation.…”

Thrombin Generation in the Glasgow Myocardial Infarction Study

“…For aspirin an effect in platelet poor plasma is not to be expected, although one recent report indicates a trend for accelerated thrombin formation in long-term aspirin users [13]. The use of statins might have attenuated thrombin generation in platelet poor plasma, as reported in several studies [14]–[16]. The fact that we did not observe any effects may have been due to the relatively low percentage of statin users in the present study.…”

A Pilot Randomized Study of Atorvastatin As Adjunct Therapy in Patients with Acute Venous Thromboembolism

“…We chose atorvastatin because it was widely available as a generic compound (whereas rosuvastatin was a brand-name only compound during the time of study period). Moreover, atorvastatin had previously been shown to reduce thrombin generation in patients with cardiovascular disease or diabetes (28,31). Second, we started atorvastatin within 3 weeks of the index acute VTE, along with anticoagulation, instead of waiting until after patients had stopped anticoagulation.…”